• Publications
  • Influence
Abiraterone in metastatic prostate cancer without previous chemotherapy.
TLDR
Abiraterone improved radiographic progression-free survival, showed a trend toward improved overall survival, and significantly delayed clinical decline and initiation of chemotherapy in patients with metastatic castration-resistant prostate cancer.
NCCN clinical practice guidelines in oncology: prostate cancer.
Apalutamide Treatment and Metastasis‐free Survival in Prostate Cancer
TLDR
Among men with nonmetastatic castration‐resistant prostate cancer, metastasis‐free survival and time to symptomatic progression were significantly longer with apalutamide than with placebo.
Changes in body composition during androgen deprivation therapy for prostate cancer.
TLDR
GnRH agonists increase weight and percentage fat body mass and decrease percentage lean body mass, fat distribution, and muscle size in men with nonmetastatic prostate cancer.
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.
TLDR
GnRH agonist treatment for men with locoregional prostate cancer may be associated with an increased risk of incident diabetes and cardiovascular disease and the benefits of GnRH agonists should be weighed against these potential risks.
Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
TLDR
Zoledronic acid increases bone mineral density in the hip and spine during androgen deprivation therapy for nonmetastatic prostate cancer and was well tolerated.
...
...